GLP-1 agonists

Glucagon-like peptide-1 receptor agonists are moving far beyond their established uses for managing type 2 diabetes ...

AUGUST 15, 2025

In a study presented at DDW 2025, GLP-1s appeared to protect patients with chronic pancreatitis from developing ...

AUGUST 13, 2025

There is little evidence to show an increased risk for aspiration pneumonia in surgical patients taking ...

MAY 31, 2025

Despite increasing demand for GLP-1 drugs, these medications are often excluded from coverage in employer health ...

MAY 28, 2025

Most patients can continue taking GLP-1 receptor agonists before undergoing elective surgery, according to new ...

APRIL 25, 2025

More than 70% of people without diabetes who receive a GLP-1 agonist to lower weight eventually stop taking it ...

APRIL 11, 2025

GLP-1 manufacturers are aggressively pursuing multiple legal and regulatory strategies to stop compounding of the ...

MARCH 6, 2025

GLP-1 agonists and SGLT2 inhibitors should be temporarily withheld prior to elective surgery to avoid ...

FEBRUARY 28, 2025

503A compounding pharmacies can expect more inspections from their state boards of pharmacy and audits from PBMs ...

FEBRUARY 13, 2025

The FDA has officially removed tirzepatide from its drug shortage list, meaning that compounding pharmacies will no ...

DECEMBER 20, 2024

The FDA has issued several warnings in 2024 to healthcare providers and patients about the risks of obtaining GLP-1 ...

DECEMBER 18, 2024

People with diabetes treated with GLP-1 agonists were 20% less likely to experience VTEs than similar patients who ...

DECEMBER 16, 2024